Ultragenyx Pharmaceutical (RARE) Capital Expenditures (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Capital Expenditures data on file, last reported at $1.0 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $1.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 million (down 25.6% YoY), and the FY2025 annual result was $5.0 million, down 28.57% from the prior year.
• Capital Expenditures grew to $1.0 million in Q1 2026 per RARE's latest filing, from -$62000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $36.6 million in Q3 2023 and troughed at -$32.7 million in Q4 2023.
• A 5-year average of $2.4 million and a median of $1.0 million in 2025 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 1516.56% in 2023 and fell as far as 1221.48% in 2023.
• A 5-year view of Capital Expenditures shows it stood at -$2.5 million in 2022, then sank by 1221.48% to -$32.7 million in 2023, then surged by 100.5% to $163000.0 in 2024, then slumped by 138.04% to -$62000.0 in 2025, then soared by 1712.9% to $1.0 million in 2026.
• Business Quant data shows RARE's Capital Expenditures at $1.0 million in Q1 2026, -$62000.0 in Q4 2025, and $1.3 million in Q3 2025.